

# Polyzois Makras

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3942743/polyzois-makras-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110  
papers

2,329  
citations

24  
h-index

45  
g-index

118  
ext. papers

2,907  
ext. citations

4.4  
avg, IF

5.42  
L-index

#	Paper	IF	Citations
110	Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 1291-1296	6.3	197
109	Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. <i>Orphanet Journal of Rare Diseases</i> , <b>2013</b> , 8, 72	4.2	195
108	Irisin in metabolic diseases. <i>Endocrine</i> , <b>2018</b> , 59, 260-274	4	109
107	Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. <i>Endocrine-Related Cancer</i> , <b>2005</b> , 12, 683-99	5.7	101
106	Endocrine manifestations in Langerhans cell histiocytosis. <i>Trends in Endocrinology and Metabolism</i> , <b>2007</b> , 18, 252-7	8.8	82
105	OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
104	SUN-LB65 Circulating Micrnas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
103	Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 169-176	6.5	67
102	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 2220-2228	6.3	64
101	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. <i>European Journal of Endocrinology</i> , <b>2018</b> , 179, R31-R45	6.5	63
100	High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. <i>Clinical Endocrinology</i> , <b>2009</b> , 71, 772-8	3.4	62
99	Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 677-683	6.5	54
98	Novel therapies for osteoporosis. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1199-214	12.7	54
97	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. <i>Therapeutics and Clinical Risk Management</i> , <b>2012</b> , 8, 295-306	2.9	54
96	Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. <i>Clinical Endocrinology</i> , <b>2007</b> , 67, 917-22	3.4	53
95	Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH). <i>Neuroradiology</i> , <b>2006</b> , 48, 37-44	3.2	48
94	Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy. <i>Neuroendocrinology</i> , <b>2010</b> , 92 Suppl 1, 60-4	5.6	45

93	Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 3206-12	5.6	42
92	Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 1206-1213	5.6	39
91	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 499-503	3.4	37
90	Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2008</b> , 4, 514-23		30
89	Bone disease in primary hyperparathyroidism. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 80, 57-65	12.7	28
88	Effect of 4 weeks of basic military training on peripheral blood leucocytes and urinary excretion of catecholamines and cortisol. <i>Journal of Sports Sciences</i> , <b>2005</b> , 23, 825-34	3.6	25
87	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , <b>2012</b> , 50, 1130-4	4.7	24
86	Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	24
85	Incidence of hip fractures in Greece during a 30-year period: 1977-2007. <i>Osteoporosis International</i> , <b>2013</b> , 24, 1579-85	5.3	23
84	Medical treatment of hypercalcaemia. <i>Hormones</i> , <b>2009</b> , 8, 83-95	3.1	23
83	Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. <i>Hormone and Metabolic Research</i> , <b>2014</b> , 46, 145-9	3.1	22
82	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. <i>Hormones</i> , <b>2011</b> , 10, 174-95	3.1	22
81	Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1291-7	12.7	21
80	Outbreak of meningococcal disease after an influenza B epidemic at a Hellenic Air Force recruit training center. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, e48-50	11.6	21
79	Off-label uses of denosumab in metabolic bone diseases. <i>Bone</i> , <b>2019</b> , 129, 115048	4.7	20
78	Combination and sequential treatment in women with postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 477-490	4	18
77	Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH). <i>Pituitary</i> , <b>2005</b> , 8, 169-74	4.3	18
76	The diagnosis and differential diagnosis of endogenous Cushing's syndrome. <i>Hormones</i> , <b>2006</b> , 5, 231-50	3.1	18

75	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , <b>2019</b> , 127, 401-418	4.7	16
74	Bazedoxifene for the treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1201-1210	4.0	15
73	Coexistence of Graves disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature. <i>Metabolism: Clinical and Experimental</i> , <b>2013</b> , 62, 1350-6	12.7	15
72	No effect of rosuvastatin in the zoledronate-induced acute-phase response. <i>Calcified Tissue International</i> , <b>2011</b> , 88, 402-8	3.9	15
71	Paget disease of bone and calcium homeostasis: focus on bisphosphonate treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2011</b> , 119, 519-24	2.3	15
70	Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2016</b> , 8, e2016033	3.2	15
69	Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. <i>Bone Reports</i> , <b>2020</b> , 12, 100267	2.6	14
68	Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 1386-9	5.6	14
67	Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2008</b> , 101, 31-40	2.7	14
66	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , <b>2016</b> , 34, 447-56	2.9	13
65	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 145-57	5.9	13
64	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , <b>2020</b> , 138, 115478	4.7	13
63	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , <b>2019</b> , 120, 44-49	4.7	13
62	Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek population. <i>Archives of Osteoporosis</i> , <b>2018</b> , 13, 111	2.9	13
61	Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. <i>Osteoporosis International</i> , <b>2013</b> , 24, 2127-32	5.3	11
60	Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1137-1144	5.9	11
59	Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2007</b> , 19, 1154-9	2.2	11
58	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. <i>Hormones</i> , <b>2019</b> , 18, 65-70	3.1	11

57	Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 69, 107-111	12.7	10
56	The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece. <i>Archives of Osteoporosis</i> , <b>2019</b> , 14, 39	2.9	10
55	Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 819-22	3	10
54	Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. <i>Molecular Therapy</i> , <b>2012</b> , 20, 6-7	11.7	10
53	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. <i>Expert Opinion on Therapeutic Targets</i> , <b>2015</b> , 19, 299-306	6.4	9
52	Extra-skeletal effects of bisphosphonates. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 110, 154264	12.7	9
51	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 93, 100-102	12.7	8
50	Performance of the mini nutritional assessment score in the detection of vitamin D status in an elderly Greek population. <i>Hormone and Metabolic Research</i> , <b>2012</b> , 44, 896-9	3.1	8
49	The annual incidence of Langerhans cell histiocytosis among adults living in Greece. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28422	3	7
48	Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. <i>Bone</i> , <b>2009</b> , 44, 766-71	11.7	7
47	A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels. <i>Gynecological Endocrinology</i> , <b>2011</b> , 27, 384-90	2.4	7
46	Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, E618-21	5.6	7
45	Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, E282-6	5.6	6
44	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	6
43	Cladribine therapy in adults with advanced Langerhans cell histiocytosis. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1541-3	1.9	6
42	Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature. <i>Hormones</i> , <b>2012</b> , 11, 419-27	3.1	6
41	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. <i>Maturitas</i> , <b>2021</b> , 147, 19-25	5	6
40	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e4155-e4162	5.6	6

39	Evaluation of the first fracture liaison service in the Greek healthcare setting. <i>Archives of Osteoporosis</i> , <b>2017</b> , 12, 3	2.9	5
38	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. <i>Calcified Tissue International</i> , <b>2018</b> , 103, 107-108	3.9	5
37	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. <i>Calcified Tissue International</i> , <b>2021</b> , 108, 587-594	3.9	5
36	Bone metabolism in Langerhans cell histiocytosis. <i>Endocrine Connections</i> , <b>2018</b> , 7, R246-R253	3.5	5
35	Bisphosphonates or denosumab discontinuation and risk of fractures. <i>Maturitas</i> , <b>2017</b> , 102, 75	5	4
34	The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. <i>Clinical Endocrinology</i> , <b>2012</b> , 77, 816-22	3.4	4
33	Systemic and endocrine manifestations of Langerhans cell histiocytosis: current concepts in diagnosis and management. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2007</b> , 2, 773-783	4.1	4
32	GH deficiency in adults. <i>Hormones</i> , <b>2003</b> , 2, 217-8	3.1	4
31	Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis. <i>Medical Hypotheses</i> , <b>2011</b> , 77, 109-11	3.8	3
30	Langerhans cell histiocytosis in an adult patient manifested as recurrent skull lesions and Diabetes Insipidus. <i>Hormones</i> , <b>2004</b> , 3, 59-64	3.1	3
29	Growth without growth hormone (GH): a case report. <i>Hormones</i> , <b>2004</b> , 3, 259-65	3.1	3
28	Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , <b>2020</b> , 69, 516-518	4.18	3
27	Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	3
26	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
25	Gender Predilection in Sporadic Parathyroid Adenomas. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
24	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , <b>2021</b> , 24, 338-340	3.5	3
23	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. <i>Journal of Clinical Densitometry</i> , <b>2021</b> , 24, 591-596	3.5	3
22	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , <b>2018</b> , 17, 573-579	3.1	3

21	Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans cell histiocytosis. <i>Pituitary</i> , <b>2012</b> , 15 Suppl 1, S28-32	4.3	2
20	Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma. <i>Journal of Musculoskeletal Neuronal Interactions</i> , <b>2019</b> , 19, 379-384	1.3	2
19	Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. <i>Bone Reports</i> , <b>2021</b> , 15, 101128	2.6	2
18	Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.. <i>Blood</i> , <b>2022</b> ,	2.2	2
17	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 71, 198-201	12.7	1
16	Periostin and sclerostin levels in juvenile Paget disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , <b>2017</b> , 14, 269-271		1
15	Bisphosphonate Therapy in Langerhans Cell Histiocytosis: An International Retrospective Descriptive Study. <i>Blood</i> , <b>2015</b> , 126, 2209-2209	2.2	1
14	Experience gained from the implementation of the fracture liaison service in Greece. <i>Archives of Osteoporosis</i> , <b>2020</b> , 15, 12	2.9	1
13	Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas. <i>JBMR Plus</i> , <b>2021</b> , 5, e10431	3.9	1
12	Hypoparathyroidism: is it that easy to treat?. <i>Hormones</i> , <b>2019</b> , 18, 55-63	3.1	0
11	Skeletal implications of isolated bone marrow mastocytosis. <i>Haematologica</i> , <b>2011</b> , 96, e27; author reply e28	6.6	0
10	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. <i>Bone</i> , <b>2022</b> , 158, 116354	4.7	0
9	Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the "ACROSS" study. <i>Archives of Osteoporosis</i> , <b>2020</b> , 15, 163	2.9	0
8	Β̄sin levels in postmenopausal women with an incident hip fracture. <i>Endocrine</i> , <b>2021</b> , 73, 719-722	4	0
7	Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. <i>Hormones</i> , <b>2020</b> , 19, 581-591	3.1	0
6	Romozosumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. <i>Bone</i> , <b>2022</b> , 154, 116209	4.7	0
5	Prevalence of the mutation in Greek adults with Langerhans cell histiocytosis.. <i>Pediatric Hematology and Oncology</i> , <b>2022</b> , 1-9	1.7	
4	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. <i>Journal of Musculoskeletal Neuronal Interactions</i> , <b>2019</b> , 19, 253-257	1.3	

- 3 Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, L89-90 5.6
- 2 Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. *Endocrine*, **2021**, 73, 223-225 4
- 1 Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians' criteria in the choice of treatment. *Hormones*, **2016**, 15, 413-422 3.1